The response rates of KIT inhibitors seem to be enhanced in patients with KIT-mutant mucosal tumours particularly in exons 11 and 13 with mutations of exon 17 associated with lower progression free survival in multi-variate analysis of prospective and retrospective trials [46]. Here, KIT is linked to neoplasm.